Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, 792 Elizabeth St., Melbourne, VIC, 3000, Australia.
Ragon Institute of MGH, MIT and Harvard University, 400 Technology Square, Cambridge, MA, 02139, USA.
Retrovirology. 2017 Dec 21;14(1):57. doi: 10.1186/s12977-017-0380-3.
The results of the RV144 HIV vaccine, in combination with several recent non-human primate vaccine studies continue to highlight the potentially protective role of non-neutralizing Fc functional antibodies in HIV vaccine design. For many currently licensed vaccines, assays that detect antigen-specific antibody titers or neutralization levels have been used as a correlate of protection. However, antibodies can confer protection through multiple other mechanisms beyond neutralization, or mechanisms which are not dependent on total antibody titers. Alternative strategies that allow us to further understand the precise mechanisms by which antibodies confer protection against HIV and other infectious pathogens is vitally important for the development of future vaccines. Systems serology aims to comprehensively survey a diverse array of antibody features and functions, in order to simultaneously examine the mechanisms behind and distinguish the most important antibody features required for protection, thus identifying key targets for future experimental vaccine testing. This review will focus on the technical aspects required for the application of Systems serology and summarizes the recent advances provided by application of this systemic analytical approach.
RV144 HIV 疫苗的结果，结合最近的几项非人类灵长类动物疫苗研究，继续强调了非中和性 Fc 功能抗体在 HIV 疫苗设计中的潜在保护作用。对于许多目前获得许可的疫苗，检测抗原特异性抗体滴度或中和水平的检测已被用作保护的相关性。然而，抗体可以通过中和以外的多种其他机制提供保护，或者不依赖于总抗体滴度的机制。允许我们进一步了解抗体如何针对 HIV 和其他传染病病原体提供保护的确切机制的替代策略，对于未来疫苗的开发至关重要。系统血清学旨在全面检测各种抗体特征和功能，以便同时研究背后的机制，并区分保护所需的最重要的抗体特征，从而确定未来实验疫苗测试的关键目标。本综述将重点介绍应用系统血清学所需的技术方面，并总结应用这种系统分析方法所提供的最新进展。
